

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with application dated
July 28, 2010,

1. Centerpoint Medical Center of Independence, LLC
(d/b/a Centerpoint Medical Center)
2. 19600 East 39th Street
Independence, MO 64097

3. License number 24-18655-01 is **renewed** in its entirety to read as follows:4. Expiration date **January 31, 2021**5. Docket No. 030-13994
Reference No.

- | | | |
|---|----------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As needed |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As needed |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. As needed (not to exceed one curie of iodine-131) |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

CONDITIONS

10. Licensed material shall be used at the licensee's facilities located at 19600 East 39th Street, Independence, Missouri, and materials listed in Subitems 6.A, 6.B., and 6.C. may be used at the licensee's facilities located at 19550 East 39th Street, Independence, Missouri.
11. The Radiation Safety Officer for this license is Robert F. Thompson, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user, in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-18655-01

Docket or Reference Number

030-13994

Amendment No. 53

B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

David E. Hazuka, M.D.

10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities greater than, less than or equal to 33 millicuries).

Stephen R. Kunz, M.D.

10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities greater than, less than or equal to 33 millicuries).

George William Pogson, M.D.

10 CFR 35.200.

Gwendolyn Ramsey Arnett, M.D.

10 CFR 35.100, 35.200, and 35.300.

Robert F. Thompson, M.D.

10 CFR 35.100, 35.200, and 35.300 (oral administration of sodium iodide-131).

Richard L. Cronemeyer, M.D.

10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

Paul Ren Chu, M.D.

10 CFR 35.200.

Stephen A. Bloom, M.D.

10 CFR 35.200.

James P. McGraw, M.D.

10 CFR 35.200.

Thomas L. Rosamond, M.D.

10 CFR 35.200.

Alan Schneider, M.D.

10 CFR 35.200.

Mark J. Lavin, M.D.

10 CFR 35.100, 35.200 and 35.300.

Kenneth M. Alfieri, M.D.

10 CFR 35.100, 35.200 and 35.300.

Matthew R. Catherine, M.D.

10 CFR 35.100 and 35.200.

Dipak Shah, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to iodine-131, strontium-89 and samarium-153).

Bob Green, M.D.

10 CFR 35.200.

Jeffrey W. Bissing, D.O.

10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-18655-01

Docket or Reference Number

030-13994

Amendment No. 53

Christopher McKinney, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).

Ramesh Avva, M.D.

10 CFR 35.100, 35.200, and 35.300.

Ira Cox, M.D.


10 CFR 35.100, 35.200, and 35.300.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Applications dated July 21, 2000 (excluding ATT's 10.15 and 12.1) **and July 28, 2010 (including attachments)**;
- B. Facsimile dated November 17, 2000 (excluding pages 7 and 8); and July 30, 2002; and,
- C. Letters dated April 15, 2002, March 26, 2003, April 15, 2003 (with enclosure), February 13, 2006, January 22, 2007, February 1, 2007, June 13, 2007; December 12, 2008, and March 18, 2009; and,
- D. Facsimile letters dated September 19, 2007, December 4, 2007, June 24, 2009 and July 14, 2009.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JAN 30 2011

By

Colleen Carol Casey
Materials Licensing Branch
Region III